We are live on ! Find out more
CGNT

Cogentix Medical, Inc.
CGNT

Delisted

CGNT was delisted on the 20th of April, 2018.

37 hedge funds and large institutions have $15.8M invested in Cogentix Medical, Inc. in 2016 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 5

13% more capital invested

Capital invested by funds: $14M → $15.8M (+$1.76M)

9% more funds holding

Funds holding: 3437 (+3)

0% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 8

Holders
37
Holders Change
+3
Holders Change %
+8.82%
% of All Funds
0.93%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
8
Increased
8
Reduced
8
Closed
5
Calls
Puts
Net Calls
Net Calls Change

CGNT Hedge Fund Activity: Q4 2016 in Review

37 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Cogentix Medical, Inc. (CGNT) for Q4 2016, worth a combined $15.8M — up 13% from $14M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new CGNT positions and 5 closed out — a net gain of 3 holders — while 8 added to existing stakes and 8 trimmed.

The largest buyer was Broadfin Capital, opening a new position worth an estimated $1.54M. The largest seller was OrbiMed, exiting entirely with an estimated $1.6M sold.

  • 37 institutional investors held Cogentix Medical, Inc. (CGNT) as of Q4 2016, up from 34 in Q3 2016.
  • Funds reported $15.8M of Cogentix Medical, Inc. stock for Q4 2016, up 13% quarter-over-quarter.
  • 8 funds opened new Cogentix Medical, Inc. positions in Q4 2016 and 5 closed out, a net change of +3 holders.
  • The largest Cogentix Medical, Inc. buyer in Q4 2016 was Broadfin Capital, an estimated $1.54M added.
  • The largest Cogentix Medical, Inc. seller in Q4 2016 was OrbiMed, an estimated $1.6M sold.

Based on aggregated 13F filings for Q4 2016.